JJ_Logo_SingleLine_Red_RGB.png
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
14 juin 2024 03h00 HE | Janssen Cilag International NV
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of...
Biolojic.Design_Logo_vertical_color - resized.jpg
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
03 juin 2024 11h00 HE | Biolojic Design
Biolojic Design Enters into Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany in oncology and immunology
Regeneron Logo.jpg
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
31 mai 2024 01h05 HE | Regeneron Pharmaceuticals, Inc.
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Regeneron Logo.jpg
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
31 mai 2024 01h00 HE | Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
28 mai 2024 03h00 HE | Medigene AG
Planegg/Martinsried, May 28, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
22 mai 2024 11h20 HE | Kymera Therapeutics, Inc.
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting ...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
21 mai 2024 04h00 HE | Medigene AG
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T...
22157.jpg
Immunology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2016 - Company A-Z, Therapy Focus and Technology Type
16 mai 2024 10h45 HE | Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
15 mai 2024 09h00 HE | Medigene AG
Planegg/Martinsried, May 15, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
14 mai 2024 07h30 HE | Medigene AG
Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for IND filing in 3Q 2024 and CTA filing in 4Q...